Quantum BioPharma grants stock options

Quantum BioPharma Ltd. announced the grant of 572,500 stock options to directors, officers, employees, and consultants. Each option is exercisable at C$4.80 for five years, expiring August 20, 2031. Of these, 172,500 vested immediately, and 400,000 are subject to performance-based vesting. The options are subject to a four-month-and-one-day hold period and were granted under the company's omnibus equity incentive plan approved by shareholders on June 29, 2023. The company also provided background on its subsidiary Lucid Psycheceuticals Inc. Inc., which is developing Lucid-MS for multiple sclerosis, and its 19.48% ownership in Unbuzzd Wellness Inc. Inc., with royalty arrangements on sales of unbuzzd products.